Sernova Biotherapeutics (HAM:PSH0) EBITDA Margin %: 0.00% (As of Apr. 2026)


HAM:PSH0 Sernova Biotherapeutics Inc HAM:PSH0
28 GF Score
Price €0.05
! 2 Warning Signs
View Full Analysis

What is Sernova Biotherapeutics EBITDA Margin %?

Sernova Biotherapeutics HAM:PSH0 -22.00% 28 EBITDA Margin % is 0.00% as of Apr. 2026. GuruFocus rates HAM:PSH0 with a GF Score™ of 28/100. The stock has 2 warning signs investors should review. Among 944 Biotechnology companies, Sernova Biotherapeutics ranks worse than 105932.1% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Sernova Biotherapeutics's EBITDA for the three months ended in Apr. 2026 was €-1.43 Mil. Sernova Biotherapeutics's Revenue for the three months ended in Apr. 2026 was €0.00 Mil. Therefore, Sernova Biotherapeutics's EBITDA margin for the quarter that ended in Apr. 2026 was 0.00%.

Sernova Biotherapeutics  (HAM:PSH0) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Sernova Biotherapeutics EBITDA Margin % Related Terms

Sernova Biotherapeutics EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Sernova Biotherapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sernova Biotherapeutics EBITDA Margin % Chart

Sernova Biotherapeutics Annual Data
Trend Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24 Oct25
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Sernova Biotherapeutics Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

HAM:PSH0 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, Sernova Biotherapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sernova Biotherapeutics EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sernova Biotherapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Sernova Biotherapeutics's EBITDA Margin % falls into.


HAM:PSH0
28GF Score
Sernova Biotherapeutics Inc HAM:PSH0
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sernova Biotherapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Sernova Biotherapeutics's EBITDA Margin % for the fiscal year that ended in Oct. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Oct. 2025 )/Revenue (A: Oct. 2025 )
=-8.989/0
= %

Sernova Biotherapeutics's EBITDA Margin % for the quarter that ended in Apr. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Apr. 2026 )/Revenue (Q: Apr. 2026 )
=-1.432/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Sernova Biotherapeutics (HAM:PSH0) has a EBITDA Margin % of 0.00% as of Apr. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sernova Biotherapeutics and its competitors. According to the industry distribution chart, Sernova Biotherapeutics ranks #999999 out of 944 companies in the Biotechnology industry.
Is Sernova Biotherapeutics' EBITDA Margin % too high?
Sernova Biotherapeutics' current EBITDA Margin % is 0.00%. Based on the distribution chart, Sernova Biotherapeutics ranks #999999 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Sernova Biotherapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Sernova Biotherapeutics' EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sernova Biotherapeutics ranks #999999 out of 944 companies for EBITDA Margin %. This places Sernova Biotherapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sernova Biotherapeutics and its competitors. Sernova Biotherapeutics's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sernova Biotherapeutics stock overvalued right now?
Sernova Biotherapeutics (HAM:PSH0) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Sernova Biotherapeutics' overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Sernova Biotherapeutics (HAM:PSH0), the current EBITDA Margin % is 0.00% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sernova Biotherapeutics Business Description

Address RPO Central Parkway, PO Box 29592, Mississauga, ON, CAN, L5A 4H2
Sernova Biotherapeutics Inc is a clinical-stage biotechnology company focused on advancing regenerative medicine for the treatment of chronic diseases. The Company's primary asset is its proprietary Cell Pouch, a bio-hybrid organ system designed to enhance the delivery of cell therapy by replicating natural body functions. The Cell Pouch creates a vascularized, organ-like environment that promotes the longevity and functionality of therapeutic cells and ensures containment for retrievability.
28GF Score

Get the complete analysis for HAM:PSH0

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.05
Price